Abstract

Background: Leukotriene E 4 (LTE 4) and histamine excreted into the urine reflect the in vivo synthesis and release of cysteinyl leukotrienes and histamine, respectively. We examined the diurnal variation of the excretion rate of these mediators over 4 consecutive days in normal subjects ( n = 5) and patients with stable mild-to-moderate asthma ( n = 8). Methods: Sixteen consecutive 6-hour urine samples were collected over 4 days. Urinary LTE 4 concentrations were determined by reverse-phase high-pressure liquid chromatography, followed by ELISA. Urinary histamine concentrations were measured by ELISA. The excretion rates of these compounds were normalized relative to urinary creatinine content. Results: The mean urinary LTE 4 excretion rate was 83.8 ± 38.2 pg/mg creatinine (mean ± SD) in normal subjects; in patients with asthma, the urinary LTE 4 excretion rate (110.0 ± 59.2 pg/mg creatinine) was significantly higher than that in normal subjects ( p < 0.05). The urinary histamine excretion rate was not different between normal subjects (24.0 ± 12.5 ng/mg creatinine) and patients with asthma (31.5 ± 25.8 ng/mg creatinine). A robust and systematic within-day variation ( p < 0.01), but no day-to-day variation, was observed in histamine excretion rate. Although the magnitude of variation in LTE 4 excretion within a day was significantly greater in patients with asthma than in normal subjects ( p < 0.05), we could not identify any specific diurnal variation pattern in either the normal or the asthma group. No significant correlation was observed between urinary LTE 4 and histamine excretion rate within any subject. Conclusions: Patients with asthma excrete LTE 4 in the urine at a greater rate than normal subjects. Although no systematic variation in urinary LTE 4 excretion rates over the course of a day was observed in either normal subjects or patients with stable asthma, the presence of a systematic diurnal variation of urinary histamine excretion exists in both groups. (J A LLERGY C LIN I MMUNOL 1995;96:643-51.)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.